Tag Archives: TXMD

Analysts’ Top Healthcare Picks: TherapeuticsMD (TXMD), Heron Therapeutics (HRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TherapeuticsMD (TXMD – Research Report), Heron Therapeutics (HRTX – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. TherapeuticsMD (TXMD)

Oppenheimer Thinks TherapeuticsMD’s Stock is Going to Recover

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares opened today at $4.76, close to its 52-week low of $4.34. Olson noted:

TherapeuticsMD (TXMD) Receives a Buy from Cantor Fitzgerald

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $27. The company’s shares opened today at $5.26. Tanner said: “We reiterate the Overweight rating and

Analysts Offer Insights on Healthcare Companies: TherapeuticsMD (NYSE MKT: TXMD) and Eli Lilly & Co (NYSE: LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TherapeuticsMD (NYSE MKT:TXMD) and Eli Lilly & Co (NYSE:LLY) with bullish sentiments. TherapeuticsMD (TXMD) In a report released yesterday, William Tanner from

Oppenheimer Maintains Their Buy Rating on TherapeuticsMD (TXMD)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares closed yesterday at $6.71. Olson noted: “We met management for an update on

Oppenheimer Keeps a Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $14. The company’s shares opened today at $6.36. Olson noted: “TXMD provided a business update including initial results for the